S229
Clinical - Breast
ESTRO 2026
cosmetic outcomes. Results:
disease-free at the end of follow-up. Conclusion: Integrating radiotherapy with immediate reconstruction is feasible and increasingly safe. Advances in radiotherapy planning and reconstructive techniques have improved outcomes compared with traditional approaches. Hypo- and ultrahypofractionated PMRT regimens are well tolerated after IBR. Importantly, patient satisfaction does not always mirror clinical results, underscoring the need to prioritize patient-centered care and multidisciplinary collaboration. References: Kaidar-Person, O., Vrou Offersen, B., Hol, S., Arenas, M., Aristei, C., Bourgier, C., Cardoso, M. J., Chua, B., Coles, C. E., Engberg Damsgaard, T., Gabrys, D., Jagsi, R., Jimenez, R., Kirby, A. M., Kirkove, C., Kirova, Y., Kouloulias, V., Marinko, T., Meattini, I., Mjaaland, I., Poortmans, P. (2019). ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant- based immediate reconstruction for early stage breast cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 137, 159– 166. https://doi.org/10.1016/j.radonc.2019.04.010 Keywords: Postmastectomy Radiotherapy Digital Poster Highlight 1003 Stereotactic Accelerated Partial Breast Irradiation Using CyberKnife – 5-Year Results of a single- institution Phase II trial. Norbert Mészáros 1,2 , Viktor Smanykó 1,2 , Gábor Stelczer 1 , Maya Rosta 2 , Zoltán Nagy Takácsi 1,3 1 Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary. 2 Department of Clinical Oncology, Semmelweis University, Budapest, Hungary. 3 Department of Radiotherapy, Semmelweis University, Budapest, Hungary Purpose/Objective: To present the five-year outcomes of stereotactic accelerated partial breast irradiation (SAPBI) following breast-conserving surgery (BCS) in patients with low- risk, early-stage invasive breast cancer. Material/Methods: Between November 2018 and November 2022, 71 patients with low-risk, early-stage invasive breast cancer (Stage I–II) who underwent BCS were enrolled in this phase II prospective study. SAPBI was delivered using a CyberKnife M6 system at a total dose of 25 Gy (4 × 6.25 Gy). Respiratory motion was monitored with implanted gold markers and a synchronised tracking system. The endpoints included local, regional, and distant control, overall survival (OS), toxicity, and
The mean age was 63.5 years. All treatments were completed as planned, respecting dose constraints. The median follow-up was 61 months (range 24–73). At last follow-up, all patients were alive, resulting in a 5-year OS rate of 100%. One patient developed bilateral breast recurrence (5-year LRFS 98.6%), and one experienced pulmonary metastasis (5-year MFS 98.3%).Mean surgical cavity volume was 8.78 cm ³ (range 0.99–30.01 cm ³ ), CTV 59.5 cm ³ (range 10.16– 134.02 cm ³ ), and PTV_EVAL 82.05 cm ³ (range 17.12– 170.9 cm ³ ).No acute or late toxicities ≥ grade 2 were observed. Early G1 erythema occurred in 9 (12.7%) and G1 edema in 7 (9.8%) patients; G1 pain was reported by 2 (2.7%). Late G1 skin changes appeared in 3 (4.2%), and 7 (9.8%) reported G1 pain. Mammography showed G1 fibrosis in 32 (45.0%) and fat necrosis in 13 (18.3%) patients.Physicians rated cosmetic outcomes as excellent/good in 94.4% (67 patients), and patients in 95.8% (68 patients); fair/poor outcomes were 5.6% (4 patients) and 4.2% (3 patients), respectively. Conclusion: SAPBI delivered with CyberKnife is a safe and effective postoperative option for early-stage invasive breast cancer, providing excellent local control, mild toxicity, and outstanding cosmetic results after five years of follow-up. Keywords: S-APBI, CyberKnife, Reported outcomes with three hypofractionated adjuvant radiotherapy schedules in patients with breast cancer. BUDHI SINGH YADAV 1 , Monsu Rathod 1 , Divya Dahiya 2 , Siddhant Khare 2 , Ngangom Robert 1 , Gaurav Trivedi 1 , Satinder Kaur 1 , Parsee Tomar 1 1 Radiotherapy & Oncology, PGIMER, Chandigarh, India. 2 General Surgery, PGIMER, Chandigarh, India Purpose/Objective: Hypofractionated adjuvant radiotherapy is becoming a new standard in patients with breast cancer. In this study we report cosmetic outcomes with three hypofractionated adjuvant radiotherapy schedules in patients with breast cancer. Material/Methods: Breast cancer patients post breast conservation surgery were included in this prospective study. These patients were part of two randomised trials (HRBC NCT04075058 and HYPART NCT04472845). Patients were treated with a radiotherapy dose of 40 Gy/15 fractions/3 weeks, 34 Gy/10 fractions/2 weeks and 26 Gy/5 fractions/1 week. Boost dose was 8 Gy/2 fractions/2 days with sequential or simultaneous Poster Discussion 1041
Made with FlippingBook - Share PDF online